Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial Of Soquelitinib For Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial Of Soquelitinib For Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases
索克利替尼是一种潜在的同类首创的iTK抑制剂，在癌症和免疫疾病中具有广阔的潜力
There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA
目前尚无完全批准的用于治疗复发的PTCL的药物，而索克利替尼已获得美国食品药品管理局的孤儿药认定和快速通道认证。
BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). The clinical trial is a randomized, controlled study that will evaluate the efficacy and safety of soquelitinib compared to standard of care chemotherapy.
加利福尼亚州伯林格姆，2024年9月10日（GLOBE NEWSWIRE）——临床阶段生物制药公司Corvus Pharmicals, Inc.（纳斯达克股票代码：CRVS）今天宣布，它已启动一项针对复发/难治性外周T细胞淋巴瘤（PTCL）患者的索克利替尼的注册性3期临床试验。该临床试验是一项随机对照研究，将评估索克利替尼与标准护理化疗相比的疗效和安全性。